Celgene Corporation Elects John Weiland to Its Board of Directors
February 15 2018 - 7:30AM
Business Wire
Celgene Corporation (NASDAQ: CELG) today announced the election
of John Weiland to its Board of Directors. Mr. Weiland has over 30
years in the healthcare industry and was most recently the
President and Chief Operating Officer of C. R. Bard, Inc. (Bard),
with worldwide responsibility for all of Bard's business operations
prior to it being acquired by Becton, Dickinson and Company (BD) in
December 2017.
Mr. Weiland joined Bard in 1996. Prior to becoming President and
COO, Mr. Weiland held the position of Group President of Bard and
had global responsibility for Bard Medical Division, Bard
Urological Division, Davol Inc., Bard Endoscopic Technologies
Division and Bard's Worldwide Manufacturing Operations. In
addition, Mr. Weiland also had responsibility for Bard's businesses
in Latin America, Mexico, Canada, the Far East and Japan. Mr.
Weiland served as a director of Bard since 2005 and prior to it
being acquired by BD.
Mr. Weiland started his career at Baxter/American Hospital
Supply Corporation in 1977. He rose through numerous managerial
positions including Vice President and General Manager of the
Scientific Products Biomedical Division, Vice President and General
Manager of Baxter International - Scientific Products Division, and
Vice President East American Scientific Products Division of Baxter
Healthcare Corp. In 1989, he became President and Chief Executive
Officer of Pharmacia Diagnostics, Inc., a division of Pharmacia AB
Upsala Sweden. In 1991, he was named Senior Vice President North
America Group for Dentsply International, the world's leading
dental products manufacturer. He holds a B.S. from DeSales
University and earned an M.B.A. from New York University.
In addition to his professional activities, Mr. Weiland is
actively involved in civic affairs. In 1987, he was named a White
House Fellow and served as a Special Assistant to President
Reagan's Cabinet. Mr. Weiland is a 2012 recipient of the
prestigious Horatio Alger Award. He serves as a director of the
Horatio Alger Association, the National Committee for Quality
Health Care (NCQHC), Meridian Health System and West Pharmaceutical
Services. He also served as a member of the Board of Trustees of
DeSales University for nineteen years.
“John is an accomplished leader in the healthcare industry with
significant expertise and experience across therapeutic areas and
geographies,” said Mark Alles, Chairman and CEO of Celgene
Corporation. “His leadership and insight will help to inform and
direct Celgene’s long-term growth strategy.”
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in
the discovery, development and commercialization of innovative
therapies for the treatment of cancer and inflammatory diseases
through next-generation solutions in protein homeostasis,
immuno-oncology, epigenetics, immunology and neuro-inflammation.
For more information, please visit www.celgene.com. Follow Celgene
on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and
YouTube.
Hyperlinks are provided as a convenience and for informational
purposes only. Celgene bears no responsibility for the security or
content of external websites.
Forward-Looking Statement
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends," "estimates,"
"plans," "will," "outlook" and similar expressions. Forward-looking
statements are based on management's current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. We undertake no obligation to update any forward-looking
statement in light of new information or future events, except as
otherwise required by law. Forward-looking statements involve
inherent risks and uncertainties, most of which are difficult to
predict and are generally beyond our control. Actual results or
outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual
Report on Form 10-K and our other reports filed with
the Securities and Exchange Commission.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180215005568/en/
Investors:908-673-9628investors@celgene.comorMedia:908-673-2275media@celgene.com
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Jul 2024 to Jul 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Jul 2023 to Jul 2024